title: Cost and safety of assisted reproductive technologies for human immunodeficiency virus-1 discordant couples.
abstract: Due to significant advances in the treatment of human immunodeficiency virus type-1 (HIV-1), HIV-1 infection gradually has become a treatable chronic disease. Successfully treated HIV-positive individuals can have a normal life expectancy. Hence, more and more HIV-1 discordant couples in Taiwan and the rest of the world are seeking fertility assistance. Pre-treatment of highly active antiretroviral therapy (HAART) combined with sperm washing and RT-polymerase chain reaction examination for HIV-1 viral load has become the standard procedure to assist them to conceive. However, in order to reduce the transmission risk to the lowest level for the couple and to diminish the cost of health care for the insurance institutes or government, in vitro fertilization (IVF)-intracytoplasmic sperm injection (ICSI) therapy provides the ideal solution for HIV-1 discordant couples with infected men. Intrauterine insemination (IUI) theoretically introduces more than 10(7) times of sperm counts or semen volume to uninfected women vs IVF-ICSI. However, since some regimens of HAART may significantly decrease the sperm motility, compared to IVF-ICSI, IUI only produces 1/5 to 1/2 pregnancy rates per cycle. Given the risk of seroconversion of HIV infection which actually happens after successful treatment, IVF-ICSI for these HIV-1 seropositive men is more cost-effective and should be the first line treatment for these cases.
authors.affiliation: Ming-Yih Wu, Hong-Nerng Ho, Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 10002, Taiwan.
authors.forename: Ming-Yih
authors.initials: MY
authors.lastname: Wu
authors.affiliation: Ming-Yih Wu, Hong-Nerng Ho, Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 10002, Taiwan.
authors.forename: Hong-Nerng
authors.initials: HN
authors.lastname: Ho
keywords: Highly active antiretroviral therapy; Intracytoplasmic sperm injection; Intrauterine insemination; Seroconversion; human immunodeficiency virus-1 discordant